Lyubimova N V, Timofeiev Yu S, Sushlinskii N E
Klin Lab Diagn. 2016 Aug;61(8):466-9.
The glio-fibrillar acid protein is considered as a biomarker of astroglyal pathology in case of neurological diseases. The glio-fibrillar acidprotein is intracytoplasmatic filamentous protein specific for cellular skeleton of mature astrocytes playing important role in their differentiation. According publications' data, the highest serum concentrations of glio-fibrillar acid protein are detected in case of neurolepsia, meningitis, febrile schizophrenia, encephalitis, Alzheimer's disease, multiple sclerosis, stroke, opened cranial-cerebral injury and other critical conditions related to damage of hematoencephalic barrier. In the recent years, publications appeared considering analysis of glio-fibrillar acid protein in blood of patients with primary and metastatic brain tumors. Purpose of study To compare levels of glio-fibrillar acid protein in blood serum of patients with primary and metastatic brain tumors and also patients with neurological diseases of non-tumorous etiology and healthy individuals. Material and methods. The analysis was applied to levels of glio-fibrillar acid protein in blood serum of neurooncologic patients (n=175) and also patients with pathology of brain of non-tumorous etiology i.e. degenerate and cerebrovascular diseases (n=38). The control group consisted of 52 healthy individuals with no principal differences in gender and age from examined groups of patients. The concentration of glio-fibrillar acid protein was established in blood serum using immune enzyme analysis in reagents of “BioVendor” firm. Results and discussion. The analysis of results of detection of glio-fibrillar acid protein demonstrated that in patients with primary malignant brain tumors the initial levels of marker were reliably higher than compared with groups of healthy individuals, patients with benign neoplasms, patients with cerebral metastases, and also in case of non-tumorous pathology. The levels of glio-fibrillar acid protein achieve their maximum in case of glioblastoma. The obtained results permit assuming existence of relationship between increasing of content of glio-fibrillar acid protein in blood serum and damage of hematoencephalic barrier permeability in case of development of malignant neoplasms of brain. Conclusion. The obtained data testify higher specificity and sensitivity of glio-fibrillar acid protein as a biochemical marker of glioblastoma appropriate to be applied in case of primary examination of patients with brain affection.
胶质纤维酸性蛋白被认为是神经疾病情况下星形胶质细胞病变的生物标志物。胶质纤维酸性蛋白是成熟星形胶质细胞细胞骨架特有的胞质丝状蛋白，在其分化过程中起重要作用。根据出版物数据，在精神错乱、脑膜炎、发热性精神分裂症、脑炎、阿尔茨海默病、多发性硬化症、中风、开放性颅脑损伤以及其他与血脑屏障损伤相关的危急情况下，检测到血清中胶质纤维酸性蛋白浓度最高。近年来，出现了一些关于分析原发性和转移性脑肿瘤患者血液中胶质纤维酸性蛋白的出版物。研究目的：比较原发性和转移性脑肿瘤患者以及非肿瘤性病因的神经疾病患者和健康个体血清中胶质纤维酸性蛋白的水平。材料和方法：对神经肿瘤患者（n = 175）以及非肿瘤性病因的脑部病变患者（即退行性和脑血管疾病患者，n = 38）血清中的胶质纤维酸性蛋白水平进行分析。对照组由52名健康个体组成，其性别和年龄与受试患者组无显著差异。使用“BioVendor”公司试剂中的免疫酶分析法测定血清中胶质纤维酸性蛋白的浓度。结果与讨论：胶质纤维酸性蛋白检测结果分析表明，原发性恶性脑肿瘤患者中该标志物的初始水平与健康个体组、良性肿瘤患者组、脑转移患者组以及非肿瘤性病变患者相比，确实更高。胶质纤维酸性蛋白水平在胶质母细胞瘤患者中达到最高。所得结果表明，在脑恶性肿瘤发生时，血清中胶质纤维酸性蛋白含量增加与血脑屏障通透性受损之间可能存在关联。结论：所得数据证明胶质纤维酸性蛋白作为胶质母细胞瘤的生化标志物具有更高的特异性和敏感性，适用于脑部疾病患者的初步检查。
